ACL-Carbon

ACL-Carbon is a biotechnology company focused on the development and commercialization of therapies targeting ATP citrate lyase (ACL), a key enzyme in the cholesterol biosynthesis pathway. The company's primary focus is on addressing unmet needs in cardiovascular health, particularly for patients with hypercholesterolemia and atherosclerotic cardiovascular disease. Their lead product is a first-in-class, oral, once-daily small molecule inhibitor designed to lower LDL cholesterol by inhibiting ACL, which acts upstream of HMG-CoA reductase. By providing an alternative mechanism to statins, ACL-Carbon aims to offer effective treatment options for patients who require additional LDL-C lowering or are statin-intolerant. The company continues to explore the potential of ACL inhibition in other metabolic and inflammatory conditions.